Immunohistochemical analysis further confirmed that Gel/G4-Arg/DOX treatment was associated with reduced expression of the M2 macrophage marker CD163 and increased expression of the M1 marker CD11c, indicating a favorable shift in the ratio of anti-tumor to pro-tumor macrophage phenotypes. This evidence concerns the gene ITGAX and neoplasm.